Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Actavis Will Acquire Rival Warner Chilcott
by Rick Mullin
May 27, 2013
| A version of this story appeared in
Volume 91, Issue 21
Generic drug producer Actavis has agreed to acquire Dublin-based Warner Chilcott in a deal that the companies value at $8.5 billion, including debt. The acquisition will create a drugmaker with approximately $11 billion in annual revenues. It will also be the third-largest specialty pharmaceutical company in the U.S., with expertise in urology and women’s health. Actavis itself has been an acquisition target in recent months, with reports of bids for the firm being made by Valeant Pharmaceuticals and Mylan.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X